CIViC Evidence Items
265 evidence items indexed
Evidence Level Distribution
CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).
AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale
Gene × Evidence Type
Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.
| Predictive | Diagnostic | Prognostic | Functional | Predispos. | Oncogenic | |
|---|---|---|---|---|---|---|
| BCR::ABL1 | 323 | 11 | ||||
| BRAF | 186 | 4 | 26 | 2 | 1 | |
| EGFR | 248 | 12 | 3 | 2 | ||
| EML4::ALK | 64 | |||||
| ERBB2 | 142 | 2 | ||||
| FLT3 | 55 | 2 | 21 | |||
| KIT | 102 | 3 | 7 | |||
| KRAS | 159 | 4 | 24 | 4 | ||
| PIK3CA | 156 | 16 | 4 | |||
| PTEN | 53 | 1 | 3 | 1 | 2 | 1 |
| TP53 | 52 | 40 | 100 | 2 | ||
| VHL | 5 | 2 | 3 | 635 | 15 |
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
| Level | Gene | Variant | Type | Direction | Significance | Disease | Drugs | Source |
|---|---|---|---|---|---|---|---|---|
| B | EGFR | Mutation | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Afatinib | Miller et al., 2012 |
| C | EGFR | L858R OR EGFR Exon 19 Deletion | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Gefitinib | Yu et al., 2014 |
| C | EGFR | T790M | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Gefitinib,Erlotinib | Pao et al., 2005 |
| D | EGFR | T790M | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Lapatinib | Li et al., 2008 |
| B | EGFR | Wildtype | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Gefitinib | Mok et al., 2009 |
| B | EGFR | L858R | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Gefitinib | Douillard et al., 2010 |
| B | EGFR | L858R OR EGFR Exon 19 Deletion | Predictive | Supports | Sensitivity/Response | Lung Adenocarcinoma | Erlotinib | Rosell et al., 2012 |
| C | EGFR | E746_A750del | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Gefitinib | Pao et al., 2004 |
| C | EGFR | Mutation | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Erlotinib | Brugger et al., 2011 |
| C | EGFR | D770_N771insGL | Predictive | Supports | Resistance | Lung Adenocarcinoma | Erlotinib | Yasuda et al., 2013 |
| B | EGFR | Rare Exon 18-21 Mutation | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Gefitinib,Erlotinib | Wu et al., 2011 |
| B | EGFR | L858R OR EGFR Exon 19 Deletion | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Erlotinib,Gefitinib | Wu et al., 2011 |
| C | EGFR | D770delinsGY | Predictive | Supports | Resistance | Lung Adenocarcinoma | Erlotinib | Yasuda et al., 2013 |
| B | EGFR | Gain-of-function | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Gefitinib | Lynch et al., 2004 |
| B | EGFR | Mutation | Predictive | Supports | Sensitivity/Response | Peritoneal Mesothelioma | Cytoreductive Surgery,Hyperthermic Intraperitoneal Chemotherapy | Foster et al., 2010 |
| B | EGFR | Amplification | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Gefitinib,Erlotinib | Dahabreh et al., 2011 |
| B | EGFR | Amplification | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Erlotinib,Gefitinib | Zhang et al., 2017 |
| B | EGFR | Mutation | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Erlotinib | Zhou et al., 2011 |
| A | EGFR | L858R OR EGFR Exon 19 Deletion | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Dacomitinib | Wu et al., 2017 |
| B | EGFR | Exon 19 Deletion | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Anti-PD1 Monoclonal Antibody | Hastings et al., 2019 |
| B | EGFR | Exon 19 Deletion | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Anti-PD-L1 Monoclonal Antibody | Hastings et al., 2019 |
| A | EGFR | Exon 20 Insertion | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Amivantamab | Park et al., 2021 |
| A | EGFR | Exon 20 Insertion | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Mobocertinib | Zhou et al., 2021 |
| A | EGFR | L858R OR EGFR Exon 19 Deletion | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Gefitinib | Douillard et al., 2014 |
| A | EGFR | Exon 20 Insertion | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Amivantamab,Chemotherapy | Zhou et al., 2023 |
| A | EGFR | L858R OR EGFR Exon 19 Deletion | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Amivantamab,Lazertinib | Felip et al., 2024 |
| A | EGFR | L858R OR EGFR Exon 19 Deletion | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Pemetrexed,Carboplatin,Amivantamab | Passaro et al., 2024 |
| A | EGFR | Mutation | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Datopotamab Deruxtecan Regimen | Sands et al., 2025 |
| A | EGFR | Mutation | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Datopotamab Deruxtecan | Ahn et al., 2025 |
| A | EGFR | S768_D770dup OR EGFR A767_V769dupASV | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Sunvozertinib | Yang et al., 2025 |
| A | EGFR | H773_V774insH OR EGFR D770_N771insG OR EGFR H773_V774insNPH OR EGFR A763_Y764insFQEA OR EGFR V774_C775insHV OR EGFR H773_V774insPH OR EGFR H773_V774insAH OR EGFR D770_N771insH OR EGFR N771dup | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Sunvozertinib | Yang et al., 2025 |
| A | EGFR | D770delinsGY OR EGFR D770_N771insY OR EGFR N771_P772insT OR EGFR H773_V774insGNPH OR EGFR A767_S768insTLA OR EGFR S768_V769insLDS OR EGFR V769_D770insCV OR EGFR V769_D770insGA OR EGFR V769_D770insGVASV OR EGFR D770delinsAS | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Sunvozertinib | Yang et al., 2025 |
| A | EGFR | D770_N771insGT OR EGFR D770_N771insD OR EGFR D770_N771insF OR EGFR D770_N771insGD OR EGFR D770_N771insT OR EGFR N771delinsCH OR EGFR N771delinsGF OR EGFR N771delinsRD OR EGFR N771delinsSQRGH OR EGFR N771_P772insDN | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Sunvozertinib | Yang et al., 2025 |
| A | EGFR | N771delinsGY OR EGFR P772_H773insYNP OR EGFR N771_P772insRH OR EGFR N771_P772insVDN OR EGFR P772delinsHR OR EGFR P772_H773insDNP OR EGFR P772_H773insPHP OR EGFR P772_H773insQ OR EGFR P772_H773insRNP OR EGFR H773delinsNPY OR EGFR H773delinsPNPY | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Sunvozertinib | Yang et al., 2025 |
| A | EGFR | H773delinsYNPY OR EGFR H773delinsYPNPY OR EGFR H773_V774insHPH OR EGFR H773_V774insTH OR EGFR C775_R776insNPHVC | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Sunvozertinib | Yang et al., 2025 |
| A | EGFR | Exon 20 Insertion | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Sunvozertinib | Yang et al., 2025 |
| B | EGFR | L858R | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Erlotinib,Gefitinib | Lim et al., 2014 |
| B | EGFR | T790M | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Gefitinib | Kobayashi et al., 2005 |
| C | EGFR | T790M | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Erlotinib,Pemetrexed | Li et al., 2014 |
| B | EGFR | L858R | Prognostic | Supports | Better Outcome | Lung Non-small Cell Carcinoma | Douillard et al., 2014 | |
| B | EGFR | Amplification | Prognostic | Supports | Poor Outcome | Barrett's Adenocarcinoma | Marx et al., 2010 | |
| B | EGFR | Amplification | Prognostic | Supports | Poor Outcome | Cervical Squamous Cell Carcinoma | Iida et al., 2011 | |
| B | EGFR | Overexpression | Prognostic | Supports | Poor Outcome | Brain Glioblastoma Multiforme | Shinojima et al., 2003 | |
| B | EGFR | Overexpression | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | Park et al., 2015 |
| D | EGFR | T790M | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Rociletinib | Walter et al., 2013 |
| B | EGFR | Overexpression | Prognostic | Supports | Poor Outcome | Head And Neck Squamous Cell Carcinoma | Rubin Grandis et al., 1998 | |
| B | EGFR | Overexpression | Predictive | Does Not Support | Sensitivity/Response | Esophagus Squamous Cell Carcinoma | Nimotuzumab | Jia et al., 2016 |
| B | EGFR | Overexpression | Prognostic | Supports | Poor Outcome | Esophagus Squamous Cell Carcinoma | Jia et al., 2016 | |
| B | EGFR | Overexpression | Predictive | Does Not Support | Sensitivity/Response | Head And Neck Squamous Cell Carcinoma | Docetaxel,Cetuximab | Tinhofer et al., 2011 |
| B | EGFR | Amplification | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Panitumumab,Cetuximab | Shen et al., 2014 |